On October 13, GENSCRIPT BIO fell 7.26% in regular trading, retreating to HK$37.5 with turnover reaching HK$111 million. The decline comes as the broader Hong Kong biotechnology and AIDD concept sector faces renewed selling pressure, with peers such as XTALPI and INSILICO also weakening amid cautious market sentiment.

The stock had accumulated substantial gains recently, driven by its strategic collaborations with Nvidia and Eli Lilly's TuneLab platform, which positioned the company within the AI drug discovery wet-lab ecosystem. After the sharp rally, profit-taking and sector-wide valuation compression triggered a concentrated wave of selling. While institutional investors like FMR LLC have been increasing their stakes in recent weeks, short-term price swings remain heavily influenced by AIDD theme rotation and liquidity conditions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)